Lilly to Participate in Evercore ISI HealthCONx Conference
Get Alerts LLY Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.6%
EPS Growth %: -20.2%
Join SI Premium – FREE
A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for approximately 90 days.
About Lilly
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news or follow us on Facebook, Instagram and LinkedIn. F-LLY
Refer to: | Jordan Bishop; [email protected]; 317-473-5712 (Media) |
Joe Fletcher; [email protected]; 317-296-2884 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-participate-in-evercore-isi-healthconx-conference-301986604.html
SOURCE Eli Lilly and Company
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Progress -- XellSmart Unveiled Phase I Results of Off-the-Shelf Parkinson's Disease Cell Therapy at MDS & Completed Blinded Phase II Enrollment
- Beware the Tax Man: Ken Jennings Wants to Tax Every Washingtonian
- New Cryptocurrency to Watch: Remittix Nears $33 Million as AVAX Trades Near $10 and Utility Takes Centre Stage
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share